Pathway Targeting, Antimycobacterial Drug Design
Delineation of (mycobacterial) pathways/networks is essential for the identification of novel target(s) so as to hit the pathogen at its vulnerable weakest. In any given pathway or network, the potential (antitubercular) drug targets are the nonhomologous proteins that form (1) unique nodes including chokepoints (enzymes that uniquely consume/produce a metabolite) and (2) nodes with a high degree centrality. For instance, the metabolic pathways/networks have been extensively implicated in antitubercular drug discovery over recent years (Ducati et al. 2007; Raman et al. 2009; Kim et al. 2010).
Tuberculosis (TB) has scourged the humankind for centuries, earning morbid nicknames such as The White Plague and The Captain of all the Men of Death. Robert Koch identified the causative agent, Mycobacterium tuberculosis, in 1882 and the first – and so far the only – vaccine against the disease, BCG (bacillus...
- Parida BK, Douglas T, Nino C, Dhandayuthapani S (2005) Interactions of anti-sigma factor antagonists of Mycobacterium tuberculosis in the yeast two-hybrid system. Tuberculosis (Edinb) 85:347–355Google Scholar
- Tyagi JS, Sharma D (2004) Signal transduction systems of mycobacteria with special reference to M. tuberculosis. Curr Sci 86:93–102Google Scholar